Objectives: The objective of this study was to evaluate the prevalence of hyperuricemia in PsA patients and to identify the associated factors. Methods: Design: cross-sectional study, including consecutive, unselected, adult PsA patients. Data collection: demographic variables (age, gender, disease duration), clinical variables (affected joints, current moderate/severe psoriasis, nail disease, axial involvement, enthesitis, dactylitis), biological factors (acute phase reactants), treatment-related variables (non-steroidal antiinflamatory drugs, corticosteroids, synthetic and biologic disease modifying drugs) and comorbidities [2]. Hyperuricemia was defined as uric acid level above 6.8 mg/dl [3]. Statistical analysis: the factors that were potentially associated with hyperuricemia were assessed by Spearman correlation and uni-and multivariate logistic regressions. Results: In all, 120 PsA patients were included in the study: 69 (57.5%) women, mean age±standard deviation 54±11.8 years, mean disease duration 7±7.4 years; 24 (20%) had moderate/severe psoriasis and 30 (25%) were taking a biologic. A high percentage of patients had cardiovascular comorbidities, i.e., dyslipidemia 80%, hypertension 51.7%, obesity 34.2% and cardiovascular events 34.2%. Around a quarter of patients had hyperuricemia (33; 27.5%). Hyperuricemia was significantly associated with obesity, diabetes, ischemic heart disease and hypertension, but there was no correlation with current skin psoriasis. In the multivariate analysis, it was best explained by diabetes (odds Background: An association between increased adiposity, obesity (Obs), and psoriasis has emerged. In addition to obesity, patients with psoriasis are more likely to have metabolic syndrome. Objectives: to evaluate the prevalence of endocrine diseases, nutritional and metabolic disorder (ENMD) comorbidity in patients (pts) with PsA and Psoriasis (PsO) patients without arthritis in the dermatological hospital cohort. Methods: 889 pts (Male-516/Female-329) with moderate-to-severy plaque PsO, mean age 50.4±17.6 years, mean PsO duration 21.5±14.7 were included. PsO pts with Endocrine, nutritional and metabolic diseases (E00-E90) (ENMD), including Disorders of thyroid gland (E00-E07), Obesity and other hyperalimentation (E65-E68), Diabetes mellitus (E10-E14) (DM) were identify in the hospital Database reporting and coding by International Statistical Classification of Disease and Related Health Problems (ICD-10) between 2010 -2015 years. M±m, t-test, χ 2 , (%) were calculated. All p<0.05 were considered to indicate statistical significance. Results: 302 out of 889 pts (33.9%) had PsA and 587 out of 889 pts (66.1%) had PsO alone. PsA pts were older then PsO pts -55.3±13.7 and 50.4±17.6 (p<0.001). 155 out of 889 pts (17.4%) had ENMD. In PsA pts ENMD were found in significantly more cases than in PsO pts -in 76 out of 302 pts (25.2%) and in 79 out of 587 pts (13.5%) accordingly (χ 2 =18.986, df=2, p<0.00001). In PsA pts ENMD coding as E00-E07 were found in significantly more cases than in PsO pts -in 25 out of 302 pts (8.3%) and in 23 out of 587 pts (3.9%) accordingly (χ 2 =7.4211, df=2, p=0.00645). Obs coding as E65-E68 were found in significantly more cases in PsA pts compare to PsO pts -in 54 out of 302 pts (17.9%) and in 64 out of 587 pts (10.9%) accordingly (χ 2 =8.4345, df=2, p=0.00368). DM coding as E10-E14 were found in more cases in PsA pts compare to PsO pts -in 54 out of 302 pts (17.9%) and in 83 out of 587 pts (14.1%) accordingly (χ 2 =2.1410, df=2, p=0.14341). Conclusions: ENMD comorbidities are common for PsA and PsO without arthritis pts. Obs and disorders of thyroid gland were found in significantly more cases in PsA pts compare to PsO pts. Obesity and PsA are an unhealthy combination. Obesity may represent an additive cardio-metabolic risk factor in PsA subjects. High frequency of ENMD in PsA than PsO could be due to share inflammation pathways with insulin resistance and age. Patients with more severe psoriasis are at higher odds of endocrine, nutritional and metabolic diseases compared with those with mild psoriasis.
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Conclusions:
The nationwide study is the first survey for real-world clinical practice of PsA in Asia and provides detailed messages about the diagnostic difficulties and therapeutic consideration, especially rationales and unmet needs on current biologic therapies, which may offer possible directions for new drug development. We also made interdisciplinary comparison, hence in order to improve comprehensive care. 
